Skip to content

Psilocybin and microdosing

Studies whose primary subject is both Psilocybin and Microdosing, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, Microdosing, micro-dosing, then ranked by relevance.

The research on psilocybin microdosing is mixed: large observational surveys and naturalistic cohorts report perceived improvements in mood, mental health, and cognition, but controlled trials and reviews generally fail to confirm these benefits beyond placebo or expectancy. The best-controlled evidence (a small RCT in major depressive disorder and a double-blind crossover study) found no advantage over placebo for mood or anxiety, and an umbrella review found only a small decrease in cognitive control. The main caveats are small controlled samples, high expectancy and blind-breaking, reliance on self-report, and limited long-term safety data.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Motives and Side-Effects of Microdosing With Psychedelics Among Users 2019 cross-sectional survey 1116 Mixed Performance enhancement was the main motive for microdosing, negative effects were mostly acute psychological effects, and the most common reason for stopping was lack of effectiveness.
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study 2022 double-blind placebo-controlled experiment 34 No effect Acute subjective effects were stronger than placebo only in participants who correctly identified their condition, with reduced theta EEG power, but no effects on well-being, creativity, or cognition apart from small changes toward cognitive impairment.
Psychedelic microdosing benefits and challenges: an empirical codebook 2019 mixed-methods Unclear Compiles participant-reported benefits and challenges into a taxonomy intended to frame future microdosing research targets.
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. 2019 observational cohort 1000 Supports Repeated spaced microdoses of LSD were followed by improvements in negative moods, especially depression, and increases in positive moods, energy, and work effectiveness in self-reports.
Microdosing psychedelics: Motivations, subjective effects and harm reduction 2019 cross-sectional survey 525 Mixed Participants microdosed mainly for mental health, personal development, and cognitive enhancement, and reported perceived short-term benefits in mood, connection, and cognition alongside unwanted effects such as stronger-than-expected psychedelic effects and anxiety.
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities 2020 cross-sectional survey 909 Mixed Microdosers were less likely to report histories of substance use or anxiety disorders but more likely to report recent recreational substance use than non-microdosers.
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study 2021 randomized controlled trial No effect Psilocybin microdosing did not affect emotion processing or symptoms of anxiety and depression compared with placebo, and did not affect interoceptive awareness.
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review 2020 systematic review Mixed Reports highly contradictory results showing both benefits and detriments of microdosing for mood, creative processes, and energy, with limitations including gender bias and heterogeneous dosing.
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention 2020 cross-sectional survey 6753 Mixed Participants often reported enhanced mood, creativity, focus, and sociability, the most common challenge was 'none', most did not test their substances, and an approach-intention predicted fewer rather than more benefits.
Microdosing psilocybin for chronic pain: a case series 2022 case series 3 Supports Self-administered low-dose psilocybin produced pain relief without psychedelic effects in three patients, with relief sometimes magnified by exercise and repeated dosing.
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls 2022 naturalistic observational study 1133 Supports Psilocybin microdosing was associated with small- to medium-sized improvements in mood and mental health across gender, age, and mental health status, with psychomotor improvements specific to older adults.
Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study 2021 preregistered field and lab crossover study Mixed Participants reported more awe during psilocybin microdosing than placebo, but about two-thirds broke blind, suggesting expectancy effects may drive subjective benefits.
Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats 2018 experimental study 40 Opposes Intermittent microdoses of psilocin or ketamine produced a mildly anxiogenic profile in rats, most significant at lower doses, though the conclusion was tentative.
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. 2023 experimental study Supports Repeated low doses of psilocybin were well tolerated, imparted stress resilience, reduced compulsive-like grooming, and increased 5-HT7 receptor expression and synaptic density in the paraventricular thalamic nucleus.
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease 2023 review Opposes Psychedelics and MDMA can bind the 5-HT2B receptor, and chronic microdosing is a potential but unconfirmed risk for valvular heart disease, with no adequately designed animal or clinical studies found.
Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure 2026 theoretical Unclear Argues that dosing schedule should be treated as an independent pharmacological variable, noting the first dedicated randomized trial in major depressive disorder (2 mg psilocybin weekly) did not beat placebo and that continuous exposure remains inadequately tested.
Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis 2026 theoretical Unclear Proposes that daily low-dose psilocybin may induce progressive 5-HT2A receptor desensitization, with fading subjective effects marking an adaptive state, and states this hypothesis is not evidence of efficacy.
The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing 2026 systematic review 3262 Mixed Some studies suggested improvements in well-being, mental health, cognition, and other outcomes, but evidence was low certainty with high risk of bias and self-reported outcomes, and adverse events were rarely reported.
Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 preclinical experimental study No effect Chronic psilocin microdosing did not affect locomotor activity, depressive-like behavior, sociability, or novelty seeking and did not increase dentate gyrus cell proliferation, though a small anxiogenic effect was observed.
Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis 2026 umbrella review 1614 Opposes The only significant pooled effect was a small decrease in cognitive control, and mood benefits were not replicated under placebo-controlled conditions.
Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT 2026 observational study Mixed Psilocybin microdosing showed subtle EEG effects including reduced global field power and frequency-specific delta and theta microstate changes, with no significant broadband changes, unlike broader alterations under acute DMT.
Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults 2026 cross-sectional survey 1523 Unclear Lifetime microdosing prevalence was 5.3% for psilocybin and 4.8% for LSD, with psilocybin more commonly microdosed for recreational than medical purposes, and microdosing more common among those with poorer mental health.
Psilocybin microdosing in the United States: Insights from a nationally representative survey 2026 survey study Unclear At least 8.4 million US adults reported lifetime psilocybin microdosing, with improving physical and mental health the top motivations.
Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial 2026 randomized controlled trial 39 No effect Four weekly 2 mg psilocybin doses produced similar reductions in depression scores to placebo (mean difference -5.4 vs -6.0), showing no statistically greater efficacy than placebo.
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial 2026 RCT protocol 40 Unclear Describes a planned double-blind placebo-controlled trial of 2 mg psilocybin versus placebo for depression; primary outcome results are not yet reported.

Points of agreement

  • Large observational surveys and naturalistic cohorts consistently report perceived improvements in mood, mental health, focus, and creativity with microdosing.
  • Controlled trials and reviews generally find no benefit over placebo for mood, anxiety, or cognition, and attribute reported benefits largely to expectancy.
  • Microdosing is widely used for self-managed mental health and performance enhancement, with dosing practices highly variable and often untested substances.
  • Adverse effects reported are mostly mild and acute, but long-term safety is poorly characterized.

Conflicts

  • Observational and self-report studies report mood and mental health benefits, while placebo-controlled trials and an umbrella review find no such benefits.
  • Animal studies disagree: one finds stress resilience and reduced compulsivity, another finds no behavioral benefit and a mildly anxiogenic profile.
  • Some surveys report minimal challenges, while others report anxiety-related and physical adverse effects.

Gaps

  • Few adequately powered placebo-controlled trials, with small samples and high rates of blind-breaking.
  • Long-term safety, including valvular heart disease risk from chronic 5-HT2B activation, is unstudied in controlled designs.
  • Optimal dosing schedule (daily vs intermittent) and dose are unresolved.
  • Populations studied are skewed toward young, white, male, online-recruited users.
  • Effects on creativity and cognition are inconsistent and not confirmed under blinding.
  • Durability of any effects beyond weeks to months is largely unknown.
Browse these studies in the library

Common questions

What does the research agree on about psilocybin and microdosing?
  • Large observational surveys and naturalistic cohorts consistently report perceived improvements in mood, mental health, focus, and creativity with microdosing.
  • Controlled trials and reviews generally find no benefit over placebo for mood, anxiety, or cognition, and attribute reported benefits largely to expectancy.
  • Microdosing is widely used for self-managed mental health and performance enhancement, with dosing practices highly variable and often untested substances.
  • Adverse effects reported are mostly mild and acute, but long-term safety is poorly characterized.
Where do studies on psilocybin and microdosing conflict?
  • Observational and self-report studies report mood and mental health benefits, while placebo-controlled trials and an umbrella review find no such benefits.
  • Animal studies disagree: one finds stress resilience and reduced compulsivity, another finds no behavioral benefit and a mildly anxiogenic profile.
  • Some surveys report minimal challenges, while others report anxiety-related and physical adverse effects.
What is still unknown about psilocybin and microdosing?
  • Few adequately powered placebo-controlled trials, with small samples and high rates of blind-breaking.
  • Long-term safety, including valvular heart disease risk from chronic 5-HT2B activation, is unstudied in controlled designs.
  • Optimal dosing schedule (daily vs intermittent) and dose are unresolved.
  • Populations studied are skewed toward young, white, male, online-recruited users.
  • Effects on creativity and cognition are inconsistent and not confirmed under blinding.
  • Durability of any effects beyond weeks to months is largely unknown.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Psilocybin and microdosing, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Psilocybin and microdosing or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

56 articles · 24 from the last two years · 25,455 participants across 27 studies reporting sample size

Common study designs

review 6 experimental study 4 cross-sectional survey 6 randomized controlled trial 5 theoretical or philosophical paper 4

Research volume by year

Compare topics →

56 studies whose primary subject is psilocybin and microdosing since 2018

Studies about psilocybin and microdosing per year, 2018 to 2026, peaking at 13 in 2026 Bar chart: one bar per year, taller where more studies were published that year. 0 10 20 2020 2025
2026 is partial
Show the numbers
Studies about psilocybin and microdosing per year, 2018 to 2026, peaking at 13 in 2026
Year Studies
2018 1
2019 5
2020 5
2021 5
2022 9
2023 3
2024 5
2025 10
2026 13

Research

Synthesize the evidence →

Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure

Zenodo (CERN European Organization for Nuclear Research) September 27, 2026 Andrea Vittorini preprint

This hypothesis and perspective article proposes that dosing schedule should be treated as an independent pharmacological variable in psilocybin microdosing research. Existing controlled studies relevant to depression and mood have predominantly used intermittent schedules. The first dedicated randomized trial in major depressive disorder used 2 mg psilocybin once weekly and did not demonstrate...

DOI: 10.5281/zenodo.23001108 (opens in new tab)

Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis

Zenodo (CERN European Organization for Nuclear Research) September 2, 2026 Andrea Vittorini preprint

This hypothesis and perspective article proposes that uninterrupted daily low-dose psilocybin may constitute a pharmacologically distinct receptor-adaptation paradigm. Repeated 5-HT2A agonist pulses could progressively produce functional desensitization, internalization, and/or down-regulation; the fading of acute subjective effects may therefore mark the development of an adaptive state rather...

DOI: 10.5281/zenodo.22239349 (opens in new tab)

The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing

Frontiers in Psychiatry August 19, 2026 Jeni Page, Alexandra Moore, Bridget E. Hawkins et al.

IntroductionMicrodosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing...

DOI: 10.3389/fpsyt.2026.1866881 (opens in new tab) Full text (opens in new tab) Magic mushrooms Microdosing Psilocybin Psychedelic substances +1

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, Biochemistry, and Behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

DOI: 10.1016/j.pbb.2026.174231 (opens in new tab) Full text (opens in new tab) Anxiety Depression Behavioral testing Hippocampal neurogenesis +3

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis

Journal of Psychopharmacology June 28, 2026 Yiğit Özaydın, Buket Canlan Özaydın

Background: Psychedelic microdosing—repeated sub-perceptual doses of lysergic acid diethylamide (LSD) or psilocybin—has attracted scientific interest as a potential mood and cognitive intervention. The evidence base remains methodologically heterogeneous and vulnerable to expectancy bias. Methods: We conducted an umbrella review with narrative synthesis following Joanna Briggs Institute...

DOI: 10.1177/02698811261456196 (opens in new tab) Psilocybin Mood Cognition Expectancy theory +6

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT

bioRxiv Preprint Server May 5, 2026 Povilas Tarailis, Inga Griškova-bulanova preprint

Electroencephalographic (EEG) microstates provide a compact framework for characterizing the temporal organization of large-scale brain activity, yet their sensitivity to altered brain states remains insufficiently explored. In this study, we applied broadband and frequency-resolved EEG microstate analysis to resting-state EEG data from two publicly available datasets acquired under markedly...

DOI: 10.64898/2026.05.05.723034 (opens in new tab) Full text (opens in new tab)

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults

American Journal of Preventive Medicine May 4, 2026 Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner et al. 1 citation

IntroductionMicrodosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limited.MethodsA cross-sectional, web-based survey (Characterizing the Epidemiology of Cannabidiol Use Survey) of 1,523...

DOI: 10.1016/j.amepre.2026.108381 (opens in new tab) Full text (opens in new tab) MDMA Medline Young adult Drug +2

Psilocybin microdosing in the United States: Insights from a nationally representative survey

Addiction March 8, 2026 Michelle Priest, Beau Kilmer, Rajeev Ramchand et al. 1 citation

At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to report microdosing the last time they used than those who have used psilocybin more than one year ago; however, approximately 15% respondents who used psilocybin in their lifetime were unsure whether they microdosed the last time they used....

DOI: 10.1111/add.70368 (opens in new tab) Psilocybin Multinomial logistic regression Epidemiology Microdose +6

Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial

Research Square February 23, 2026 Rotem Petranker, Norman A. S. Farb, Omer A. Syed et al. preprint

Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two...

DOI: 10.21203/rs.3.rs-8319478/v1 (opens in new tab) Full text (opens in new tab) Psilocybin Major depressive disorder Placebo Adverse effect +9

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial

BJPsych Open February 16, 2026 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. 1 citation

BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...

DOI: 10.1192/bjo.2025.10968 (opens in new tab) Full text (opens in new tab)

Clinical trials

All psilocybin and microdosing trials →